Nada J. Daood

Nada J. Daood

Auto-generated profile, based on publicly available information

Nada J. Daood

Tulane University School of Medicine

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2025 in Digital Discovery
Verified
Journal Article
Open access
PDF file
SCSurid Mohammad Chowdhury
Surid Mohammad Chowdhury
NDNada J. Daood
Nada J. Daood
KLKatherine R. Lewis
Katherine R. Lewis
RSRayhanus Salam
Rayhanus Salam
HZHao Zhu
Hao Zhu
NBNathalie Busschaert
Nathalie Busschaert
The development of synthetic compounds capable of transporting chloride anions across biological membranes has become an intensive research field in the last two decades. Progress is driven by the desire to develop treatments for chloride transport related diseases (e.g., cystic fibrosis), cancer or bacterial infections. In this manuscript, we use high-throughput screening and machine learning to identify novel scaffolds, and to find the molecular features needed to achieve potent chloride transport that can be generalized across diverse chemotypes. 1894 compounds were tested, 59 of which had confirmed transmembrane chloride transport ability. A machine learning (ML) binary classification model indicated that MolLog P is the most important feature to predict transport ability, but it is not sufficient by itself. The best ML model was able to identify potential chloride transporters from the DrugBank database and the predictions were experimentally validated. These insights can provide other researchers with inspiration and guidelines to develop ever more potent chloride transporters.

27 October 2026 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
SCSean R. Carey
Sean R. Carey
XWXia Wen
Xia Wen
NDNada J. Daood
Nada J. Daood
ECElena Chung
Elena Chung
JTJacqueline B. Tiley
Jacqueline B. Tiley
HZHao Zhu
Hao Zhu
ATP-binding cassette (ABC) transporters play a critical role in transmembrane transport, and the inhibition of ABC transporter-mediated efflux can lead to unintended drug–drug interactions (DDIs). The identification of new drug candidates as perpetrators of transporter-mediated DDIs requires synthesis of significant drug products and costly experimental evaluation. Alternatively, computational approaches can rapidly and accurately screen the DDI liability of new drug candidates in silico. Here, we developed a novel DDI risk assessment protocol incorporating classic and graph-based quantitative structure–activity relationship (QSAR) models. These models were trained on publicly available, large-scale, structurally diverse in vitro chemical inhibition data for P-gp, BCRP, and MRP1. The resultant models yielded promising R2 scores (0.58 to 0.82). External predictions successfully identified inhibitors, verified by experimental validation or literature review, and detected drugs with the potential to perpetrate clinically relevant DDIs. In summary, we developed a large, diverse database of ABC transporter inhibitors and present an applicable alternative protocol that incorporates model predictions to evaluate transporter-mediated DDIs for new drug candidates to prevent potentially harmful clinical outcomes.